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Background {#Sec2}
----------

Fluralaner is a novel systemically administered isoxazoline class compound that provides immediate and persistent insecticidal and acaricidal efficacy after oral administration to dogs. A field study has shown that a single fluralaner dose administered orally to dogs provides at least 12 weeks of flea and tick control \[[@CR1]\] and another study demonstrated efficacy against mites (*Demodex* spp.) \[[@CR2]\]. Fluralaner was shown to be safe when administered orally at overdoses of up to 5 times the maximum clinical dose at 8-week intervals in healthy Beagle dogs \[[@CR3]\] and at overdoses of 3 times the maximum clinical dose in Collies bearing a homozygous defect of the multi-drug-resistance 1 gene (MDR1 −/−) \[[@CR4]\]. There are no known interactions of fluralaner with other veterinary medicinal drugs \[[@CR5]\] and fluralaner was shown to be safe when administered concurrently with macrocyclic lactones like milbemycin oxime \[[@CR6]\] and moxidectin \[[@CR7]\].

Ivermectin is registered for the use in dogs at monthly oral doses of 6 mcg/kg BW for heartworm protection \[[@CR8]\]; some veterinarians may choose to administer ivermectin at higher off label doses to treat dogs for different worm or mite infestations (for example 0.05 mg/kg for hookworm, 0.1 mg/kg BW for whipworms, 0.2 mg/kg for *Toxocara canis*, 0.2-0.4 mg/kg for sarcoptic mange, 0.2 mg/kg for nasal mites *Pneumonyssus caninum*, 0.3 mg/kg for cheyletiellosis, 0.3--0.6 mg/kg for demodicosis; orally or subcutaneous as single or repeated treatments) \[[@CR9]--[@CR20]\]; however, such high doses of ivermectin cannot safely be administered to "ivermectin-sensitive" dogs carrying a MDR1 mutation \[[@CR21], [@CR22]\]. Ivermectin is a substrate for the p-glycoprotein (p-gp) transporter encoded by the MDR1 gene \[[@CR22], [@CR23]\]. This transporter limits the entry of its substrates into the body by an efflux-based mechanism, particularly at the blood--brain barrier \[[@CR24]\]. Dogs with a homozygous defect of the MDR1 gene do not carry a functional p-glycoprotein transporter and are therefore more susceptible to neurotoxicity caused by ivermectin \[[@CR21]\]. Furthermore, drug-drug interactions at the p-glycoprotein transporter may occur following the concurrent use of ivermectin and drugs, leading to an increased risk of neurotoxicity of ivermectin in MDR1 intact dogs. One example is spinosad that inhibits the p-glycoprotein transporter-mediated elimination of ivermectin in MDR1 intact dogs, thereby increasing ivermectin blood concentrations, which leads to a higher risk of neurotoxicity when administering high off-label doses of ivermectin concurrently with spinosad \[[@CR25]--[@CR30]\].

Veterinarians may choose to administer fluralaner and ivermectin concurrently. To ensure that the concurrent use does not increase the risk of ivermectin-associated neurotoxicity, the pharmacokinetic profile of ivermectin was investigated when administered concurrently with fluralaner. For pharmacokinetic characterization over time, fluralaner and ivermectin were administered at high dose rates (i.e. 56 mg fluralaner/kg BW, the highest expected dose in clinical use, and 0.3 mg ivermectin/kg BW) and on a single occasion.

Methods {#Sec3}
-------

Thirty healthy Beagle dogs (15 males and 15 females) were included in the study. Dogs were kept indoors in pens with sealed floors and were housed in groups of two or three, with the exception of the 3 days after ivermectin/fluralaner administration, when dogs were housed individually. Dogs had access to water *ad libitum* throughout the study period and were fed a standard dog diet.

This study was conducted in Ireland in compliance with Directive 2010/63/EU S.I. No. 543 of 2012 and the Irish national animal protection legislation framework (experimental license no. B100\\4500), and the study plan was approved by the research organization institutional (Charles River Laboratories Preclinical Services Ireland Ltd.) ethics committee.

The 30 dogs were allocated to three study groups by sorting within gender according to descending body weight and random allocation to a group (Table [1](#Tab1){ref-type="table"}). Ivermectin (Ivomec Classic Injection for Cattle and Sheep; Merial Animal Health) was administered orally at a dose of 0.3 mg/kg BW and fluralaner (Bravecto™; Merck/MSD Animal Health) was administered orally at the maximum clinical dose of 56 mg/kg BW on study day 0. Blood samples for plasma concentration determination were collected prior to administration and at 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 240, 336, 504, 672, 1008, 1344, 1656 and 2016 h (84 days) after administration. Ivermectin and fluralaner blood plasma concentrations were determined using validated methods (lower limit of quantification 1 ng ivermectin/mL and 10 ng fluralaner/mL).Table 1Study groups for evaluation of the pharmacokinetic profile of ivermectin and fluralaner when administered concurrently to dogsIvermectinFluralanerIvermectin plus FluralanerIvermectin dose (mg/kg BW)0.3-0.3Fluralaner dose (mg/kg BW)-5656GenderMale555Female555Body weight (kg)Mean ± SD13.1 ± 1.213.3 ± 1.513.1 ± 1.0*SD* standard deviation

Standard pharmacokinetic parameters including maximum plasma concentration (C~max~), time to C~max~ (t~max~), the extrapolated area under the curve (AUC~∞~) and the elimination half-life (t½) were calculated using non-compartmental and linear trapezoidal methods. Statistical analysis of pharmacokinetic parameters was performed after natural logarithmic transformation, with the exception of t~max~, using ANOVA models and 90 % confidence intervals, and the individual animal being the experimental unit. Pharmacokinetic and statistical analyses were performed using SAS/STAT® (Language: Reference, Version 9.3, SAS Institute Inc., Cary, NC, USA).

Results and discussion {#Sec4}
----------------------

The plasma concentration versus time profile of ivermectin was comparable in dogs administered ivermectin only and in dogs administered ivermectin concurrently with fluralaner (Fig. [1](#Fig1){ref-type="fig"}). Similarly, the plasma concentration versus time profile of fluralaner was comparable in dogs administered fluralaner only and in dogs administered fluralaner concurrently with ivermectin (Fig. [2](#Fig2){ref-type="fig"}). The pharmacokinetic parameters of both, ivermectin and fluralaner, were also comparable across groups (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}), with no statistical significant differences between groups.Fig. 1Mean ivermectin plasma concentration (± standard deviation) in dogs following oral administration (0.3 mg/kg BW) alone or concurrently with fluralaner (56 mg/kg BW)Fig. 2Mean fluralaner plasma concentration (± standard deviation) in dogs following oral administration (56 mg/kg BW) alone or concurrently with ivermectin (0.3 mg/kg BW)Table 2Ivermectin pharmacokinetic parameters in dogs following oral administration (0.3 mg/kg BW) alone or concurrently with fluralaner (56 mg/kg BW)ParameterUnitIvermectinIvermectin plus Fluralaner*P-*valueMean ± SDMean ± SDC~max~(ng/mL)92.70 ± 26.7780.52 ± 21.410.2465t~max~(day)0.29 ± 0.100.31 ± 0.110.7269AUC~∞~(day\*ng/mL)141.96 ± 27.23134.26 ± 37.990.5073t½(days)2.07 ± 0.711.84 ± 0.420.4888*SD* standard deviationTable 3Fluralaner pharmacokinetic parameters in dogs following oral administration (56 mg/kg BW) alone or concurrently with ivermectin (0.3 mg/kg BW)ParameterUnitFluralanerFluralaner plus Ivermectin*P-*valueMean ± SDMean ± SDC~max~(ng/mL)7976 ± 42399312 ± 17670.1529t~max~(day)3.00 ± 1.493.20 ± 2.660.8379AUC~∞~(day\*ng/mL)175778 ± 75122184030 ± 495240.5373t½(days)14.27 ± 2.5313.45 ± 1.680.5107*SD* standard deviation

Conclusions {#Sec5}
-----------

Concurrent administration of fluralaner and ivermectin does not alter the pharmacokinetics of either compound. There is no evident interaction of fluralaner and ivermectin indicating an increased risk of ivermectin-associated neurotoxicity in fluralaner-treated dogs.
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